A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
2017
Background
We describe a randomized, non-blinded Phase II interventional study to assess the safety and efficacy of stereotactic ablative radiotherapy (SABR) for hormone-sensitive oligometastatic prostate adenocarcinoma, and to describe the biology of the oligometastatic state using immunologic, cellular, molecular, and functional imaging correlates. 54 men with oligometastatic prostate adenocarcinoma will be accrued. The primary clinical endpoint will be progression at 6 months from randomization with the hypothesis that SABR to all metastases will forestall progression by disrupting the metastatic process. Secondary clinical endpoints will include local control at 6 months post-SABR, toxicity and quality of life, and androgen deprivation therapy (ADT)-free survival (ADT-FS). Further fundamental analysis of the oligometastatic state with be achieved through correlation with investigational 18F–DCFPyL PET/CT imaging and measurement of circulating tumor cells, circulating tumor DNA, and circulating T-cell receptor repertoires, facilitating an unprecedented opportunity to characterize, in isolation, the effects of SABR on the dynamics of and immunologic response to oligometastatic disease.
Keywords:
- Pathology
- Cancer research
- Medicine
- Circulating tumor cell
- Androgen deprivation therapy
- Prostate cancer
- Radiation
- Surgical oncology
- Clinical endpoint
- Radiation therapy
- Adenocarcinoma
- Progression-free survival
- Oncology
- Internal medicine
- Response Evaluation Criteria in Solid Tumors
- SABR volatility model
- Randomized controlled trial
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
39
References
55
Citations
NaN
KQI